PE20230108A1 - Variantes de anticuerpos caninos - Google Patents
Variantes de anticuerpos caninosInfo
- Publication number
- PE20230108A1 PE20230108A1 PE2022002420A PE2022002420A PE20230108A1 PE 20230108 A1 PE20230108 A1 PE 20230108A1 PE 2022002420 A PE2022002420 A PE 2022002420A PE 2022002420 A PE2022002420 A PE 2022002420A PE 20230108 A1 PE20230108 A1 PE 20230108A1
- Authority
- PE
- Peru
- Prior art keywords
- igg
- canine
- variants
- substitution
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011453P | 2020-04-17 | 2020-04-17 | |
| PCT/US2021/027836 WO2021212081A1 (en) | 2020-04-17 | 2021-04-16 | Canine antibody variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230108A1 true PE20230108A1 (es) | 2023-01-25 |
Family
ID=75888187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002420A PE20230108A1 (es) | 2020-04-17 | 2021-04-16 | Variantes de anticuerpos caninos |
Country Status (17)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| AU2018318440A1 (en) | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| CN120005022A (zh) | 2019-01-03 | 2025-05-16 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗il31抗体 |
| JP7832123B2 (ja) | 2020-05-11 | 2026-03-17 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
| CN116096741B (zh) | 2020-07-10 | 2024-10-18 | 因外泰克斯公司 | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 |
| CA3194936A1 (en) * | 2020-09-28 | 2022-03-31 | Zoetis Services Llc | Canine antibody variants |
| AU2023289332A1 (en) * | 2022-06-21 | 2024-12-12 | Zoetis Services Llc | Canine antibody mutants |
| US20240254231A1 (en) | 2023-01-20 | 2024-08-01 | PetMedix Ltd. | Therapeutic antibodies |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ES2665954T3 (es) | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| JP5833145B2 (ja) * | 2011-02-04 | 2015-12-16 | ゾエティス・エルエルシー | 免疫原性bordetellabronchiseptica組成物 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
| PE20181336A1 (es) | 2015-09-18 | 2018-08-21 | Chugai Pharmaceutical Co Ltd | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| CN116271014A (zh) * | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| EP3526246A1 (en) * | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| EP3866842A4 (en) | 2018-10-18 | 2022-07-13 | Kindred Biosciences, Inc. | FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE |
| CN120005022A (zh) * | 2019-01-03 | 2025-05-16 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| KR20220066002A (ko) * | 2019-03-20 | 2022-05-23 | 킨드레드 바이오사이언시스, 인코포레이티드 | 의학적 용도의 ngf 길항제 |
| CA3194936A1 (en) * | 2020-09-28 | 2022-03-31 | Zoetis Services Llc | Canine antibody variants |
| MX2023008785A (es) * | 2021-01-28 | 2023-12-14 | Zoetis Services Llc | Mutaciones en regiones constantes de anticuerpos caninos. |
-
2021
- 2021-04-16 IL IL297287A patent/IL297287A/en unknown
- 2021-04-16 JP JP2022562645A patent/JP7879810B2/ja active Active
- 2021-04-16 CN CN202180028973.4A patent/CN115996949A/zh active Pending
- 2021-04-16 CA CA3175921A patent/CA3175921A1/en active Pending
- 2021-04-16 BR BR112022020944A patent/BR112022020944A2/pt unknown
- 2021-04-16 KR KR1020227035765A patent/KR20230005156A/ko active Pending
- 2021-04-16 PE PE2022002420A patent/PE20230108A1/es unknown
- 2021-04-16 EP EP21724863.2A patent/EP4136106A1/en active Pending
- 2021-04-16 WO PCT/US2021/027836 patent/WO2021212081A1/en not_active Ceased
- 2021-04-16 AU AU2021256056A patent/AU2021256056A1/en active Pending
- 2021-04-16 MX MX2022012866A patent/MX2022012866A/es unknown
- 2021-04-16 US US17/918,853 patent/US20230242635A1/en active Pending
- 2021-04-16 PH PH1/2022/552742A patent/PH12022552742A1/en unknown
- 2021-04-19 TW TW110113947A patent/TW202204403A/zh unknown
-
2022
- 2022-10-17 EC ECSENADI202280846A patent/ECSP22080846A/es unknown
- 2022-10-17 CL CL2022002857A patent/CL2022002857A1/es unknown
- 2022-10-18 CO CONC2022/0014695A patent/CO2022014695A2/es unknown
-
2023
- 2023-11-13 CL CL2023003377A patent/CL2023003377A1/es unknown
-
2026
- 2026-03-06 JP JP2026035921A patent/JP2026097964A/ja active Pending
- 2026-03-18 US US19/570,699 patent/US20260193342A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023003377A1 (es) | 2024-04-19 |
| JP2023522029A (ja) | 2023-05-26 |
| KR20230005156A (ko) | 2023-01-09 |
| TW202204403A (zh) | 2022-02-01 |
| ECSP22080846A (es) | 2023-02-28 |
| US20230242635A1 (en) | 2023-08-03 |
| CO2022014695A2 (es) | 2022-10-21 |
| PH12022552742A1 (en) | 2024-03-25 |
| WO2021212081A1 (en) | 2021-10-21 |
| CL2022002857A1 (es) | 2023-06-02 |
| JP2026097964A (ja) | 2026-06-16 |
| IL297287A (en) | 2022-12-01 |
| AU2021256056A1 (en) | 2022-10-20 |
| JP7879810B2 (ja) | 2026-06-24 |
| US20260193342A1 (en) | 2026-07-09 |
| CN115996949A (zh) | 2023-04-21 |
| CA3175921A1 (en) | 2021-10-21 |
| MX2022012866A (es) | 2022-11-08 |
| EP4136106A1 (en) | 2023-02-22 |
| BR112022020944A2 (pt) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| BR112016016416A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS | |
| BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
| MX2020009642A (es) | Anticuerpos monoclonales de interleucina-31 para uso veterinario. | |
| EA201991701A1 (ru) | Состав на основе моноклонального антитела к rsv | |
| MX2022006760A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| MX2016011934A (es) | Inmunoglobulina hibrida conteniendo un enlace no-peptidilico. | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| MX2021012251A (es) | Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). | |
| CL2018000238A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| BR112022022922A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso | |
| CO2018004090A2 (es) | Anticuerpos anti-tigit y métodos de uso | |
| BR112017006591A2 (pt) | polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico | |
| BR112018076260A2 (pt) | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina | |
| EA202190264A1 (ru) | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn | |
| BR112018000477A2 (pt) | proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural | |
| EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
| ATE452913T1 (de) | Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen | |
| MX393649B (es) | Vacunas y anticuerpos contra el dengue | |
| EA201892554A1 (ru) | Мутант cd200 и его применения | |
| BR112021024938A2 (pt) | Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso | |
| CL2018003072A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| MX2023005896A (es) | Variantes de anticuerpos bovinos. | |
| PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| WO2022159839A8 (en) | Monoclonal antibodies against coronaviruses and uses thereof |